Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.45 |
| ▸ | ACP1 | P24666 | 2/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4354241 | 1.00 | PTPN1 (0.45) | PTPN1ACP1PTPN2ALOX5EPHX2 | |
| SCHEMBL4350505 | 0.86 | ALOX5 (0.49) | PTPN1ACP1ALOX5PIM1MEN1 | |
| SCHEMBL4350510 | 0.86 | ALOX5 (0.49) | PTPN1ACP1ALOX5PIM1MEN1 | |
| SCHEMBL4355527 | 0.85 | ALOX5 (0.51) | PTPN1ACP1PTPN2ALOX5EPHX2 | |
| SCHEMBL4355526 | 0.85 | ALOX5 (0.51) | PTPN1ACP1PTPN2ALOX5EPHX2 | |
| SCHEMBL4351246 | 0.84 | ADAMTS5 (0.51) | PTPN1ACP1PTPN2ALOX5EPHX2 | |
| SCHEMBL4351250 | 0.84 | ADAMTS5 (0.51) | PTPN1ACP1PTPN2ALOX5EPHX2 | |
| SCHEMBL4354737 | 0.82 | PTPN1 (0.51) | PTPN1ACP1MEN1KMT2A | |
| SCHEMBL4354740 | 0.82 | PTPN1 (0.51) | PTPN1ACP1MEN1KMT2A | |
| SCHEMBL4348120 | 0.82 | MAPT (0.49) | PTPN1EPHX2PIM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1890695-B1 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | GRUENENTHAL GMBH (DE) | 2013-02-20 | — | — | EP | claimed |
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | GRUENENTHAL GMBH (DE) | 2009-08-27 | — | — | US | claimed |
| EP-1890695-A2 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | Grünenthal GmbH (DE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006122777-A2 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | claimed |
| EP-1890695-B1 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | GRUENENTHAL GMBH (DE) | 2013-02-20 | — | — | EP | disclosed |
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | GRUENENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-1890695-A2 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | Grünenthal GmbH (DE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006122777-A2 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | ABCB1, ABCG2, SLC5A2 | PTPN1 1096/4885ACP1 4133/4885PTPN2 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.